SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
文献类型：期刊论文
| 作者 | Wu, Leyun2; Zhou, Liping2; Mo, Mengxia1; Liu, Tingting3; Wu, Chengkun1; Gong, Chunye1; Lu, Kai1; Gong, Likun3 ; Zhu, Weiliang2; Xu, Zhijian2
|
| 刊名 | SIGNAL TRANSDUCTION AND TARGETED THERAPY
 |
| 出版日期 | 2022-01-05 |
| 卷号 | 7期号:1页码:3 |
| ISSN号 | 2095-9907 |
| DOI | 10.1038/s41392-021-00863-2 |
| 通讯作者 | Gong, Likun(lkgong@cdser.simm.ac.cn) ; Zhu, Weiliang(wlzhu@simm.ac.cn) ; Xu, Zhijian(zjxu@simm.ac.cn) |
| 资助项目 | Natural Science Foundation of Shanghai[21ZR1475600] ; National Key R&D Program of China[2016YFA0502301] ; National Key R&D Program of China[2017YFB0202601] ; National Science Foundation of China[U1811462] ; open fund from the State Key Laboratory of High-Performance Computing[201901-11] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Cell Biology |
| 语种 | 英语 |
| WOS记录号 | WOS:000739396400001 |
| 出版者 | SPRINGERNATURE |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/300694]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Gong, Likun; Zhu, Weiliang; Xu, Zhijian |
| 作者单位 | 1.Natl Univ Def Technol, Coll Comp Sci & Technol, Changsha 410073, Peoples R China 2.Chinese Acad Sci, Drug Discovery & Design Ctr, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China 3.Chinese Acad Sci, Ctr Drug Safety Evaluat & Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wu, Leyun,Zhou, Liping,Mo, Mengxia,et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2022,7(1):3. |
| APA | Wu, Leyun.,Zhou, Liping.,Mo, Mengxia.,Liu, Tingting.,Wu, Chengkun.,...&Xu, Zhijian.(2022).SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2.SIGNAL TRANSDUCTION AND TARGETED THERAPY,7(1),3. |
| MLA | Wu, Leyun,et al."SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2".SIGNAL TRANSDUCTION AND TARGETED THERAPY 7.1(2022):3. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。